Diabetic sequelae - Micro- and macroangiopathic organ damage;Die diabetischen folgeerkrankungen. Mikro- und makroangiopathische organschäden

Internist

Volumn 44, Issue 7, 2003, Pages 840-852

  Lichtenauer, U D ^a   Seissler, J ^a   Scherbaum, W A ^a  

^a LEIBNIZ CENTER FOR DIABETES RESEARCH AT HEINRICH HEINE UNIVERSITY DÜSSELDORF   (Germany)

Author keywords

Diabetes mellitus; Macroangiopathy; Microangiopathy; Nephropathy; Neuropathy

Indexed keywords

ACETYLSALICYLIC ACID; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; ANTITHROMBOCYTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARBAMAZEPINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GABAPENTIN; GLUCOSE; TRAMADOL; TRICYCLIC ANTIDEPRESSANT AGENT;

CEREBROVASCULAR ACCIDENT; DIABETES MELLITUS; DIABETIC ANGIOPATHY; DIABETIC FOOT; DIABETIC NEPHROPATHY; DIABETIC NEUROPATHY; DIABETIC RETINOPATHY; DISEASE ASSOCIATION; GLUCOSE BLOOD LEVEL; HUMAN; HYPERCHOLESTEROLEMIA; HYPERGLYCEMIA; HYPERTENSION; ISCHEMIC HEART DISEASE; KIDNEY FAILURE; MICROANGIOPATHY; MORTALITY; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PROGNOSIS; QUALITY OF LIFE; REVIEW; RISK FACTOR; VASCULAR DISEASE; VISUAL IMPAIRMENT;

ARTERIAL OCCLUSIVE DISEASES; CORONARY DISEASE; DIABETES COMPLICATIONS; DIABETES MELLITUS; DIABETIC ANGIOPATHIES; DIABETIC NEPHROPATHIES; DIABETIC NEUROPATHIES; HUMANS; RECEPTORS, SENSORY;

EID: 0038378015     PISSN: 00209554     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00108-003-0996-3     Document Type: Review

References (73)

1. (1995) Effect of intensive diabetes management on macrovascular events and risk factors in the Diabetes Control and Complications Trial. Am J Cardiol 75: 894-903
2. American Diabetes Association (1998) Consensus development conference on the diagnosis of coronary heart disease in people with diabetes: 10-11 February 1998, Miami, Florida. Diabetes Care 21: 1551-1559
3. UK Prospective Diabetes Study Group (1998) Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 317: 703-713
4. Abbott CA, Vileikyte L, Williamson S, Carrington AL, Boulton AJ (1998) Multicenter study of the incidente of and predictive risk factors for diabetic neuropathic foot ulceration. Diabetes Care 21: 1071-1075
5. Andersen AR, Christiansen JS, Andersen JK, Kreiner S, Deckert T (1983) Diabetic nephropathy in Type 1 (insulin-dependent) diabetes: an epidemiological study. Diabetologia 25: 496-501
6. Asplund K, Hagg E, Helmers C, Lithner F, Strand T, Wester PO (1980) The natural history of stroke in diabetic patients. Acta Med Scand 207: 417-424
7. Backonja M, Beydoun A, Edwards KR et al. (1998) Gabapentin for the symptomatic treatment of painful neuropathy in patients with diabetes mellitus: a randomized controlled trial. JAMA 280: 1831-1836
8. Biesenbach G, Grafinger P, Janko O, Zazgornik J (1997) Influence of cigarette-smoking on the progression of clinical diabetic nephropathy in type 2 diabetic patients. Clin Nephrol 48: 146-150
9. Chantelau E (1999) Pathogenesis of diabetic foot disease. Internist 40: 994-1001
10. Diaz R, Paolasso EA, Piegas LS et al. (1998) Metabolic modulation of acute myocardial infarction. The ECLA (Estudios Cardiologicos Latinoamerica) Collaborative Group. Circulation 98: 2227-2234
11. Engstrom G, Stavenow L, Hedblad B, Lind P, Eriksson KF, Janzon L, Lindgarde F (2003) Inflammation-sensitive plasma proteins, diabetes, and mortality and incidence of myocardial infarction and stroke: a population-based study. Diabetes 52: 442-447
12. Faronato PP, Maioli M, Tonolo G et al. (1997) Clustering of albumin excretion rate abnormalities in Caucasian patients with NIDDM. The Italian NIDDM Nephropathy Study Group. Diabetologia 40: 816-823
13. Fava S, Azzopardi J, Muscat HA, Fenech FF (1993) Factors that influence outcome in diabetic subjects with myocardial infarction. Diabetes Care 16: 1615-1618
14. Festa A, D'Agostino R, Howard G, Mykkanen L, Tracy RP, Haffner SM (2000) Chronic subclinical inflammation as part of the insulin resistance syndrome: the Insulin Resistance Atherosclerosis Study (IRAS). Circulation 102: 42-47
15. Forsblom CM, Sane T, Groop PH et al. (1998) Risk factors for mortality in Type II (non-insulin-dependent) diabetes: evidence ofa role for neuropathy and a protective effect of HLA-DR4. Diabetologia 41: 1253-1262
16. Frei U, Schober-Halstenberg HJ (1999) Annual report of the German Renal Registry 1998. QuaSi-Niere Task Group for Quality Assurance in Renal Replacement Therapy. Nephrol Dial Transplant 14: 1085-1090
17. Gerritsen J, Dekker JM, TenVoorde BJ et al. (2001) Impaired autonomic function is associated with increased mortality, especially in subjects with diabetes, hypertension, or a history of cardiovascular disease: the Hoorn Study. Diabetes Care 24: 1793-1798
18. Graf M, Halbach E, Kaufmann H (1999) Causes of blindness in Hessia in 1996. Klin Monatsbl Augenheilkd 215: 50-55
19. Grau AJ, Weimar C, Buggle F et al. (2001) Risk factors, outcome, and treatment in subtypes of ischemic stroke: the German stroke data bank. Stroke 32: 2559-2566
20. Haffner SM, Lehto S, Ronnemaa T, Pyorala K, Laakso M (1998) Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 339: 229-234
21. Harati Y, Gooch C, Swenson M et al. (1998) Double-blind randomized trial of tramadol for the treatment of the pain of diabetic neuropathy. Neurology 50: 1842-1846
22. Haslbeck M, Corvin S, Luft D et al. (2002) Diagnose, Therapie und Verlaufskontrolle der autonomen diabetischen Neuropathien. In: Scherbaum WA, Landgraf R (Hrsg) Evidenzbasierte Diabetes-Leitlinien. Deutsche Diabetes Gesellschaft
23. Haslbeck M, Redaélli M, Parandeh-Shab F et al. (2000) Diagnostik, Therapie und Verlaufskontrolle der sensomotorischen diabetischen Neuropathien. In: Scherbaum WA, Lauterbach KW, Renner R (Hrsg) Evidenzbasierte Diabetes-Leitlinien. Deutsche Diabetes Gesellschaft
24. Hasslacher C (1989) Diabetic nephropathy: structural-functional relationships. Contrib Nephrol 73: 24-28
25. Hasslacher C, Bostedt-Kiesel A, Kempe HP, Wahl P (1993) Effect of metabolic factors and blood pressure on kidney function in proteinuric type 2 (non-insulin-dependent) diabetic patients. Diabetologia 36: 1051-1056
26. Hasslacher C, Gandjour A, Redaélli M et al. (2000) Diagnose, Therapie und Verlaufskontrolle der Diabetischen Nephropathie. In: Scherbaum WA, Lauterbach KW, Renner R (Hrsg) Evidenzbasierte Diabetes-Leitlinien. Deutsche Diabetes Gesellschaft
27. Howard BV, Robbins DC, Sievers ML et al. (2000) LDL cholesterol as a strong predictor of coronary heart disease in diabetic individuals with insulin resistance and low LDL: The Strong Heart Study. Arterioscler Thromb Vasc Biol 20:830-835
28. Kannel WB, McGee DL (1979) Diabetes and cardiovascular risk factors: the Framingham study. Circulation 59: 8-13
29. Kempler P, Varadi A, Szalay F (1992) Autonomic neuropathy and prolongation of QT-interval in liver disease. Lancet 340: 318
30. Klein R, Klein BE, Moss SE, Davis MD, DeMets DL (1984) The Wisconsin epidemiologic study of diabetic retinopathy. II. Prevalence and risk of diabetic retinopathy when age at diagnosis is less than 30 years. Arch Ophthalmol 102: 520-526
31. Klein R, Klein BE, Moss SE, Davis MD, DeMets DL (1984) The Wisconsin epidemiologic study of diabetic retinopathy, III. Prevalence and risk of diabetic retinopathy when age at diagnosis is 30 or more years. Arch Ophthalmol 102: 527-532
32. Klein R, Klein BE, Moss SE, Davis MD, DeMets DL (1984) The Wisconsin epidemiologic study of diabetic retinopathy. IV. Diabetic macular edema. Ophthalmology 91: 1464-1474
33. Kothari V, Stevens RJ, Adler AI, Stratton IM, Manley SE, Neil HA, Holman RR (2002) UKPDS 60: risk of stroke in type 2 diabetes estimated by the UK Prospective Diabetes Study risk engine. Stroke 33: 1776-1781
34. Krumpaszky HG, Ludtke R, Mickler A, Klauss V, Selbmann HK (1999) Blindness incidence in Germany. A population-based study from Wurttemberg-Hohenzollem. Ophthalmologica 213: 176-182
35. Kuhlmann A (2001) Podozytenschaden bei experimentellem Diabetes - Effekt von ACE- und Endothelin-Hemmung. Pathologie 22: A226
36. Laakso M (1999) Hyperglycemia and cardiovascular disease in type 2 diabetes. Diabetes 48: 937-942
37. Larkins RG, Dunlop ME (1992) The link between hyperglycaemia and diabetic nephropathy. Diabetologia 35: 499-504
38. Lowel H, Koenig W, Engel S, Hormann A, Keil U (2000) The impact of diabetes mellitus on survival after myocardial infarction: can it be modified by drug treatment? Results of a population-based myocardial infarction register follow-up study. Diabetologia 43: 218-226
39. Mackaay AJ, Beks PJ, Dur AH, Bischoff M, Scholma J, Heine RJ, Rauwerda JA (1995) The distribution of peripheral vascular disease in a Dutch Caucasian population: comparison of type II diabetic and non-diabetic subjects. Eur J Vasc Endovasc Surg 9: 170-175
40. Malmberg K (1997) Prospective randomised study of intensive insulin treatment on long term survival after acute myocardial infarction in patients with diabetes mellitus. DIGAMI (Diabetes Mellitus, Insulin Glucose Infusion in Acute Myocardial Infarction) Study Group. BMJ 314: 1512-1515
41. McNeely MJ, Boyko EJ, Ahroni JH, Stensel VL, Reiber GE, Smith DG, Pecoraro RF (1995) The independent contributions of diabetic neuropathy and vasculopathy in foot ulceration. How great are the risks? Diabetes Care 18: 216-219
42. Mogensen CE, Christensen CK (1984) Predicting diabetic nephropathy in insulin-dependent patients. N Engl J Med 311: 89-93
43. Morello CM, Leckband SG, Stoner CP, Moorhouse DF, Sahagian GA (1999) Randomized double-blind study comparing the efficacy of gabapentin with amitriptyline on diabetic peripheral neuropathy pain. Arch Intern Med 159: 1931-1937
44. Neaton JD, Wentworth DN, Cutler J, Stamler J, Kuller L (1993) Risk factors for death from different types of stroke. Multiple Risk Factor Intervention Trial Research Group. Ann Epidemiol 3: 493-499
45. Ohkubo Y, Kishikawa H, Araki E et al. (1995) Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Res Clin Pract 28: 103-117
46. Quinn M, Angelico MC, Warram JH, Krolewski AS (1996) Familial factors determine the development of diabetic nephropathy in patients with IDDM. Diabetologia 39: 940-945
47. Reichard P, Pihl M, Rosenqvist U, Sule J (1996) Complications in IDDM are caused by elevated blood glucose level: the Stockholm Diabetes Intervention Study (SDIS) at 10-year follow up. Diabetologia 39: 1483-1488
48. Ritz E, Rychlik I, Locatelli F, Halimi S (1999) End-stage renal failure in type 2 diabetes: A medical catastrophe of worldwide dimensions. Am J Kidney Dis 34: 795-808
49. Ritz E, Stefanski A (1996) Diabetic nephropathy in type II diabetes. Am J Kidney Dis 27: 167-194
50. Rodriguez BL, D'Agostino R, Abbott RD et al. (2002) Risk of hospitalized stroke in men enrolled in the Honolulu Heart Program and the Framingham Study: A comparison of incidence and risk factor effects. Stroke 33: 230-236
51. Ruhnau KJ, Meissner HP, Finn JR et al. (1999) Effects of 3-week oral treatment with the antioxidant thioctic acid (alpha-lipoic acid) in symptomatic diabetic polyneuropathy. Diabet Med 16: 1040-1043
52. Savage PJ (1996) Cardiovascular complications of diabetes mellitus: what we know and what we need to know about their prevention. Ann Intern Med 124: 123-126
53. Sawicki PT (1997) Lisinopril and albumin excretion in diabetes. Lancet 350: 662-664
54. Scherbaum WA, Landgraf R (2002) Praxisleitlinien der Deutschen Diabetes Gesellschaft. Diabetes Stoffwechsel 11: 1-30
55. Schiel R, Muller UA, Sprott H, Schmelzer A, Mertes B, Hunger-Dathe W, Ross IS (1997) The JEVIN trial: a population-based survey on the quality of diabetes care in Germany: 1994/1995 compared to 1989/1990. Diabetologia 40: 1350-1357
56. Shaw JE (1999) The epidemiology of diabetic neuropathy. Diabetes Rev 7: 245-252
57. Sievers ML, Bennett PH, Nelson RG (1999) Effect of glycemia on mortality in Pima Indians with type 2 diabetes. Diabetes 48: 896-902
58. Siitonen OI, Niskanen LK, Laakso M, Siitonen JT, Pyorala K (1993) Lower-extremity amputations in diabetic and nondiabetic patients. A population-based study in eastern Finland. Diabetes Care 16: 16-20
59. Sima AA, Thomas PK, Ishii D, Vinik A (1997) Diabetic neuropathies. Diabetologia 40 (Suppl 3): B74-B77
60. Stamler J, Vaccaro O, Neaton JD, Wentworth D (1993) Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care 16: 434-444
61. Standl E, Fuchs C, Parandeh-Shab F et al. (2000) Management der Hypertonie beim Patienten mit Diabetes mellitus. In: Scherbaum WA, Lauterbach KW, Renner R (Hrsg) Evidenzbasierte Diabetes-Leitlinien. Deutsche Diabetes-Gesellschaft
62. Stone PH, Muller JE, Hartwell T et al. (1989) The effect of diabetes mellitus on prognosis and serial left ventricular function after acute myocardial infarction: contribution of both coronary disease and diastolic left ventricular dysfunction to the adverse prognosis. The MILIS Study Group. J Am Coll Cardiol 14: 49-57
63. Taubert G, Winkelmann BR, Schleiffer T et al. (2003) Prevalence, predictors, and consequences of unrecognized diabetes mellitus in 3266 patients scheduled for coronary angiography. Am Heart J 145: 285-291
64. Tierney S, Fennessy F, Hayes DB (2000) ABC of arterial and vascular disease. Secondary prevention of peripheral vascular disease. BMJ 320: 1262-1265
65. Toeller M, Buyken A, Heitkamp G et al. (1997) Protein intake and urinary albumin excretion rates in the EURODIAB IDDM Complications Study. Diabetologia 40: 1219-1226
66. Vlassara H, Cai W, Crandall J et al. (2002) Inflammatory mediators are induced by dietary glycotoxins, a major risk factor for diabetic angiopathy. Proc Natl Acad Sci U S A 99:15.596-15.601
67. Vlassara H, Fuh H, Donnelly T, Cybulsky M (1995) Advanced glycation end products promote adhesion molecule (VCAM-1, ICAM-1) expression and atheroma formation in normal rabbits. Mol Med 1: 447-456
68. Wilton TD (1974) Tegretol in the treatment of diabetic neuropathy. S Afr Med J 48: 869-872
69. Woodfield SL, Lundergan CF, Reiner JS et al. (1996) Angiographic findings and outcome in diabetic patients treated with thrombolytic therapy for acute myocardial infarction: the GUSTO-1 experience. J Am Coll Cardiol 28: 1661-1669
70. Ziegler D (1994) Diabetic cardiovascular autonomic neuropathy: prognosis, diagnosis and treatment. Diabetes Metab Rev 10: 339-383
71. Ziegler D, Gries FA, Muhlen H, Rathmann W, Spuler M, Lessmann F (1993) Prevalence and clinical correlates of cardiovascular autonomic and peripheral diabetic neuropathy in patients attending diabetes centers. The Diacan Multicenter Study Group. Diabete Metab 19: 143-151
72. Ziegler D, Hanefeld M, Ruhnau KJ et al. (1999) Treatment of symptomatic diabetic polyneuropathy with the antioxidant alpha-lipoic acid: a 7-month multicenter randomized controlled trial (ALADIN III Study). ALADIN III Study Group. Alpha-Lipoic Acid in Diabetic Neuropathy. Diabetes Care 22: 1296-1301
73. Zuanetti G, Latini R, Maggioni AP, Franzosi M, Santoro L, Tognoni G (1997) Effect of the ACE inhibitor lisinopril on mortality in diabetic patients with acute myocardial infarction: data from the GISSI-3 study. Circulation 96: 4239-4245